Wuhan YZY Biopharma Co's quarterly market cap
increased
from Jun. 2023 (HK$0.0 Mil) to Dec. 2023 (HK$1,725.3 Mil) but then
declined
from Dec. 2023 (HK$1,725.3 Mil) to Jun. 2024 (HK$1,517.8 Mil).
Wuhan YZY Biopharma Co's annual market cap
stayed the same
from Dec. 2021 (HK$0.0 Mil) to Dec. 2022 (HK$0.0 Mil) but then
increased
from Dec. 2022 (HK$0.0 Mil) to Dec. 2023 (HK$1,725.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Wuhan YZY Biopharma Co's Enterprise Value for Today is HK$902.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Wuhan YZY Biopharma Co's Market Cap
For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan YZY Biopharma Co's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Wuhan YZY Biopharma Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Wuhan YZY Biopharma Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co (HKSE:02496) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Wuhan YZY Biopharma Co Market Cap Related Terms
Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02496 has been successfully added to your